Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Amid desperate efforts to find a treatment for the neurodegenerative disease Alzheimer’s, the aducanumab saga continues, as a US Food and Drug Administration panel will determine whether a post-hoc analysis of the arrested trials EMERGE and ENGAGE could be enough to approve the drug.
This week marks our last COVID-19 Research in Brief. COVID-19 research has been progressing at a staggering speed. But a lot still needs to be uncovered to effectively fight this pandemic. We look back at 6 months of biomedical research on COVID-19.
As the current pandemic has taken scientists away from the lab, funding agencies are having to adapt to these extraordinary situations. Some are keeping true to their original plan. Others have had to make difficult decisions.